Established in 1988, Washington Biotechnology, Inc. is located in Baltimore, Maryland, U.S.A.
WBI Early-Stage Biotech/Pharma Services
WBI has a long and successful track record of providing in vivo services to emerging biotech and pharmaceutical companies in early stage development. In addition to our wide selection of disease models for cancer and inflammation, we can work with you to develop and validate custom models - with specialized expertise, economical pricing and rapid scheduling.
Washington Biotechnology, Inc. (WBI) is a leading In Vivo Services Contract Research Organization (CRO) for drug development.
For over 25 years we have provided our global biopharmaceutical clients with rapidly scheduled, accurate and cost-effective efficacy testing services.
Our clients drive innovation. We feel privileged to serve them in advancing treatments for human disease. In our role as CRO Partner, we are committed to the highest standards of science and project management.
We are continuously expanding and improving WBI's services to support our clients. This commitment sets us apart as "The In Vivo Services CRO Partner of Choice" for non-clinical in vivo efficacy testing.
Sign up for our newsletter to receive the most up-to-date information on our services.
WBI’s specialized In Vivo Efficacy Testing Services cover four major disease categories – Autoimmune and Inflammatory Diseases (including a separate category for Rheumatoid Arthritis), Cancer, Bacterial Infection and Pain. Complementary services include Pharmacokinetics (PK), Toxicity and Support Services.
CON A-Induced Hepatitis - the most important AIH research model; plays a key role in AIH drug development.
WBI has long experience testing therapeutic and prophylactic agents in well-established in vivo models for Rheumatoid Arthritis (RA) including:
WBI Human Cancer Cell Lines are available for a wide variety of cancers.
WBI offers Xenograft, Orthotopic and Syngeneic Models in both mice and rats (infusion).
Models include: Breast Cancer, Prostate Cancer, Melanoma, Myeloma, Lymphoma, Liver Cancer, Lung Cancer, Kidney Cancer, Colon Cancer, Brain Cancer and Head and Neck Cancers. WBI scientists provide expert guidance in dosing and routes of drug administration.
WBI offers a number of bacterial challenge models including Listeria monocytogenes and Methicillin Resistant Staph Aureus (MRSA).
WBI offers basic in vivo models for thermal and mechanical pain responses which may be combined with inflammation models to provide information on analgesic activity in inflamed tissue; and the Formalin Test (Chemical Sensitivity), the most predictive of models for acute pain.
WBI Services to complement disease model efficacy studies include:
Formulations – to develop a bioavailable, stable and optimal dosage form for a specific administration route.
In Vitro Compound Screening for early screening of test materials
Other services including: Tissue Culture, Bacterial Culture, Cardiovascular Screen Services, Clinical Chemistry, Cell Counts and Differentials, Necropsy and Histology.